CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas

Affiliations

¹ Department of Dermatology and Venereology, University Hospital Centre (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
² Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
³ Department of Dermatology and Venereology, University Hospital Centre (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland; Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Dermatology, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain. Electronic address: emmanuella.guenova@unil.ch.

Free article

Comment

Olesya Pavlova et al. J Invest Dermatol. 2023 Jul.

Free article

. 2023 Jul;143(7):1122-1126.

doi: 10.1016/j.jid.2023.02.011. Epub 2023 Mar 16.

¹ Department of Dermatology and Venereology, University Hospital Centre (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
² Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
³ Department of Dermatology and Venereology, University Hospital Centre (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland; Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Dermatology, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain. Electronic address: emmanuella.guenova@unil.ch.

No abstract available

Comment on

CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas.
Ta VA, Battistella M, Zhao LP, Dobos G, Ram-Wolff C, Madelaine I, Bories JC, Tournilhac O, Rouanet J, Veyrat-Masson R, Bouaziz JD, Marie-Cardine A, Bagot M, Bensussan A, Moins-Teisserenc H, De Masson A. Ta VA, et al. J Invest Dermatol. 2023 Jul;143(7):1329-1332.e3. doi: 10.1016/j.jid.2023.01.009. Epub 2023 Jan 28. J Invest Dermatol. 2023. PMID: 36716922 No abstract available.